Navigation Links
Introducing DenMat's Totally New Web Site @ DenMat.com Featuring a New On-Line Store, New Page Design & Special On-Line Savings
Date:7/26/2012

SANTA MARIA, Calif., July 26, 2012 /PRNewswire/ -- DenMat's brand new website with e-commerce functionality is live! Now all dentists will be able to log in to DenMat.com, learn about DenMat products, check out current online promotions, and make purchases in the elegantly designed e-store.

(Photo: http://photos.prnewswire.com/prnh/20120726/LA46779)

The site was created to deliver the most user-friendly direct-to-dentist online experience in dentistry. Product information is easy to find with intuitive navigation, and purchasing your favorite DenMat products has never been easier. At a glance, online customers can see what they have selected as they add to their active shopping cart, and be notified of available quantity discounts with the NEW "Best pricing" function. Additionally, all limited-time promotions can be redeemed with a single click by using the scroll bar.

"We hope that everyone will visit the new site, learn more about DenMat products and enjoy the state-of-the-art shopping experience," commented Oliver Gelles, Sr. Vice President of Marketing, DenMat. "It's designed to be informative, convenient, and deliver unbeatable value, day or night.Since we're constantly launching new products and promotional offers, it pays to visit regularly... so be sure to save DenMat.com as a favorite!"

Save Time and Money. Experience it for yourself. Visit DenMat.com TODAY, or call us at 800-445-0345. We're always glad to hear from you.

About DenMat® Holdings, LLC
DenMat® Holdings, LLC, manufactures a broad range of cosmetic, restorative and clinical product solutions, available in the U.S. and over 68 countries worldwide. Ongoing partnerships continue to position DenMat in the forefront of the dental industry. LUMINEERS, the contact- lens thin veneers placed without the need for anesthetic, extensive prepping or temporaries, is the cornerstone of DenM
'/>"/>

SOURCE DenMat Holdings, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Introducing LensWay AutoRefill - the Easiest way to Order Contact Lenses!
2. Generex Announces OncUView.tv Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012
3. Varian X-Ray Products Business Launches On-Line Product Finder for Customers
4. TeraDiscoveries to Use its Inverse Design Software Running on Windows Azure to Advance Its Computational Drug Discovery Process
5. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
6. UBM Canon and MD+DI Proudly Announce 25 Innovative Products as Winners of the 2012 Medical Design Excellence Awards
7. Breathe Technologies Non-Invasive Open Ventilation (NIOV™) System Receives Medical Design Award
8. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
9. Anthony Creed Joins DDSTUDIO As GM, Experience Design
10. CSL Behring Receives FDA Orphan Drug Designation for rIX-FP, a Novel Therapy in Development to Treat Congenital Factor IX Deficiency (Hemophilia B)
11. UBM Canon, the Global MedTech Authority, and the Medical Design Excellence Awards Honored Dr. Thomas Fogarty with the 2012 Lifetime Achievement Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... YORK , July 6, 2015 E-QURE ... Chairman, will present live at VirtualInvestorConferences.com on July 9, ... EDT LINK: http://tinyurl.com/e-qure-presentation This ... are invited to ask the company questions in real-time ... the association,s "virtual trade booth." If attendees are not ...
(Date:7/6/2015)... Array BioPharma,s (NASDAQ:   ARRY) wholly-owned ... at the 2015 ESMO World Congress of Gastrointestinal ... data were shared from a Phase 1b trial ... 2 expansion of that trial testing the combination ... or without the addition of alpelisib (BYL719) ...
(Date:7/6/2015)... FRANCISCO, Calif. , July 6, 2015 ... pharmaceutical company, and Oculeve, a development-stage medical device company ... today announced that they have entered into an agreement ... transaction.  Under the terms of the agreement, Allergan will ... commercialization milestone payments related to Oculeve,s lead development program ...
Breaking Medicine Technology:E-QURE Corp to Webcast, Live, at VirtualInvestorConferences.com July 9 2Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 2Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 3Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 4Allergan to Acquire Oculeve Dry Eye Disease Development Programs 2Allergan to Acquire Oculeve Dry Eye Disease Development Programs 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 4
... Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) today announced ... gout will be reviewed by the Arthritis Advisory Committee appointed ... 5, 2009 as required for a drug of a new ... the FDA on October 31, 2008 seeking approval to market ...
... 28 Cell Therapeutics (CTI),(Nasdaq and MTA: ... from its pivotal phase III EXTEND (PIX301) ... relapsed aggressive non-Hodgkin,s lymphoma,(NHL) treated with pixantrone ... survival, compared with other,single-agent chemotherapeutic agents ...
Cached Medicine Technology:Savient Announces FDA's Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients 2Savient Announces FDA's Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients 3Savient Announces FDA's Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients 4Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkin's Lymphoma Trial 2Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkin's Lymphoma Trial 3Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkin's Lymphoma Trial 4
(Date:7/6/2015)... Vancouver, BC (PRWEB) , ... July 06, 2015 , ... ... has received the UBC 2014-2015 Post Graduate Teaching Award on behalf of the department ... Endocrinology is a very exciting field to be practicing in. The technology is changing ...
(Date:7/6/2015)... Irvine, CA (PRWEB) , ... July 06, 2015 ... ... for disease prevention in southern California, has partnered with Woodbridge Walk-In Urgent Care ... disease, cancer, stroke and other serious medical conditions. Screenings are affordable and accurate ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... Health care ... the ability of the medical field to access and use this “Big Data” to ... MD, President and Chief Executive Officer of the Mount Sinai Health System in New ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... In a ... learn how to reduce their risk of having a fracture through the bone health ... Fractures Awareness Day. , “We are participating because our residents need this information to ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... World renowned ... the opportunity to achieve their ideal appearance through comprehensive treatment solutions. Individuals that want ... with the doctor and receive a plan that resolves each of their needs. ...
Breaking Medicine News(10 mins):Health News:Olive Fertility Centre Physician Honoured for Teaching 2Health News:Woodbridge Walk-In Offers Affordable Early Detection Health Screenings Through Longevity 2Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 2Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 3Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 4Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 5Health News:National Bone Health Screening and Awareness Day 2Health News:Los Angeles Plastic Surgeon, Dr. Paul Nassif, is Now Offering Comprehensive Facial Plastic Surgery Procedures 2
... of time between pregnancies are at an increased risk for ... had given birth twice between 1992 and 1998. Results of ... more likely to become pregnant again in less than six ... 20 years old, smoke, and live in a socially and ...
... usually prescribe antibiotics for problems like pneumonia, but ... may also protect against strokes. ,How could a ... involves the blockage of blood vessels supplying the ... blood vessels rupture and block blood flow to ...
... of anxiety and became a cultural icon, is 40 years ... stubborn streak of chemist Leo Sternbach, who refused to quit ... develop a tranquilizer to compete with a rival company's drug. ... he got the results: The compound made animals relaxed and ...
... entering the "death" phase as mortality outstrips new infections, ... the world's worst -- and this is just the ... government has been criticized for its lackluster approach to ... million South Africans.,Activists have also called on the government ...
... what is believed to be Britain's first genetically-selected baby ... ,The new baby, named Jamie, was delivered by Caesarean ... an IVF embryo, to his four-year-old brother Charlie. Charlie ... traveled to the United States for treatment after being ...
... the risk of breast cancer recurrence in post-menopausal ... are drugs that block the conversion of precursor ... inhibitors block the conversion of precursor molecules into ... study, coordinated through the National Surgical Adjuvant Breast ...
Cached Medicine News:Health News:Valium hits 40 years old, anxiety-free 2Health News:Lowering Risk of Breast Cancer Recurrence 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: